BerGenBio ASA (BGBIO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:BerGenBio ASA (BGBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8109
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ノルウェー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BerGenBio ASA (BerGenBio) is a clinical-stage biopharmaceutical company that develops drugs to treat multiple aggressive cancers. The company develops epithelial-mesenchymal transition inhibitors for acquired cancer drug-resistance and metastasis. Its BGB324 is an AXL kinase inhibitor which finds application in the treatment of drug-resistant chronic myeloid leukemia. BerGenBio’s cellselect is a drug discovery and validation technology that identifies and validates novel drug targets and biomarkers. The company’s cellselect imaging allows cell sorting, selection, and in-vivo disease imaging. Its cellselect modeling and regulated translational tools are used for disease and treatment in-vivo modeling. BerGenBio is headquartered in Bergen, Norway.

BerGenBio ASA (BGBIO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BerGenBio ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
BerGenBio ASA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
BerGenBio Raises US$6.4 Million In Venture Financing 11
BerGenBio Secures US$8.8 Million In Series A Financing 13
Partnerships 14
BerGenBio Enters into Agreement with Merck 14
Licensing Agreements 15
ADC Therapeutics Enters into Licensing Agreement with BerGenBio 15
Equity Offering 16
BerGenBio to Raise USD24 Million in Private Placement of Shares 16
BerGenBio Raises USD47 Million in IPO 17
BerGenBio Raises USD25 Million in Private Placement of Shares 18
BerGenBio Raises USD12 Million in Private Placement of Shares 19
BerGenBio Completes Private Placement Of Common Stock For US$11.9 Million 20
BerGenBio ASA – Key Competitors 21
BerGenBio ASA – Key Employees 22
BerGenBio ASA – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
May 15, 2018: BerGenBio: Results for the First Quarter 2018 24
Aug 18, 2017: BerGenBio: Results for the Second Quarter and Half year 2017 25
May 23, 2017: BerGenBio: Results for the First Quarter 2017 26
Product News 28
12/14/2017: BerGenBio to present recent highlights from its clinical trials with selective AXL inhibitor BGB324 at DNB’s 8th Annual Nordic Healthcare Conference 28
12/11/2017: BerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor BGB324 in Relapsed/Refractory AML Patients at 59th ASH Annual Meeting 29
11/17/2017: BerGenBio: Results for the Third Quarter 2017 30
11/01/2017: Clinical Study with BGB324, BerGenBios Selective First-in-Class AXL Inhibitor, Featured at the 2017 American Society of Hematology Annual Meeting 31
10/12/2017: Clinical Study with BGB324, BerGenBios Selective First-in-Class AXL Inhibitor, to be Presented at the 9th World Congress of Melanoma 32
06/06/2017: BerGenBio’s selective first-in-class Axl inhibitor, BGB324, Featured in a Poster Presentation at ASCO Annual Meeting 2017 33
01/09/2017: BerGenBio To Present At 9th Annual Biotech Showcase 2017 34
Clinical Trials 35
Jan 29, 2018: BerGenBio: Encouraging I-O clinical data with selective AXL inhibitor bemcentinib (BGB324) supports its potential as cornerstone of cancer therapy 35
Jan 09, 2018: BerGenBio Meets First Efficacy Endpoint in Phase II Trial With Selective AXL Inhibitor BGB324 (bemcentinib) in NSCLC 37
Jan 08, 2018: BerGenBio to present at Biotech Showcase 2018 38
Nov 14, 2017: BerGenBio Presents BGB324 and KEYTRUDA (pembrolizumab) Clinical Trial at the 2017 San Antonio Breast Cancer Symposium 39
Oct 19, 2017: BerGenBio Announces Start of Phase II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer 40
Sep 28, 2017: BGB324, BerGenBio’s Selective First-in-Class AXL Inhibitor, Featured in Three Clinical Presentations at the 18th World Conference on Lung Cancer 41
Jul 26, 2017: BerGenBio to Present its First-In-Class, Selective AXL Inhibitor BGB324 at Precision: Lung Cancer – World R&D Summit in Boston 42
Jun 26, 2017: BerGenBio Awarded NOK 24m from Innovasjon Norge to Support the Clinical Development of BGB324 in Combination with KEYTRUDA for Advanced Lung Cancer 43
May 19, 2017: Abstract showing activity in MDS of BerGenBio’s first-in-class AXL inhibitor, BGB324, accepted for presentation at ASCO Annual Meeting 2017 44
Other Significant Developments 45
Aug 21, 2018: BerGenBio: Results for the Second Quarter and First Half 2018 45
Feb 13, 2018: BerGenBio: Results for the Fourth Quarter and Full Year 2017 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
BerGenBio ASA, Pharmaceuticals & Healthcare, Key Facts 2
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BerGenBio ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BerGenBio ASA, Deals By Therapy Area, 2012 to YTD 2018 9
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
BerGenBio Raises US$6.4 Million In Venture Financing 11
BerGenBio Secures US$8.8 Million In Series A Financing 13
BerGenBio Enters into Agreement with Merck 14
ADC Therapeutics Enters into Licensing Agreement with BerGenBio 15
BerGenBio to Raise USD24 Million in Private Placement of Shares 16
BerGenBio Raises USD47 Million in IPO 17
BerGenBio Raises USD25 Million in Private Placement of Shares 18
BerGenBio Raises USD12 Million in Private Placement of Shares 19
BerGenBio Completes Private Placement Of Common Stock For US$11.9 Million 20
BerGenBio ASA, Key Competitors 21
BerGenBio ASA, Key Employees 22

List of Figures
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[BerGenBio ASA (BGBIO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • High Energy Batteries (India) Ltd:企業の戦略・SWOT・財務分析
    High Energy Batteries (India) Ltd - Strategy, SWOT and Corporate Finance Report Summary High Energy Batteries (India) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Neurotez Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Neurotez Inc (Neurotez) is a biotechnology company that develops and markets leptin product, a novel hormone replacement therapy for Alzheimer’s disease (AD). The company's product pipeline includes leptin, NT1, NT2, and others. Its product leptin is an adipocyte hormone that controls energy …
  • Ignyta Inc:医療機器:M&Aディール及び事業提携情報
    Summary Ignyta Inc (Ignyta), formerly NexDx Inc, a subsidiary of F. Hoffmann-La Roche Ltd, is a cancer care service provider. The company discovers, develops and commercializes new drugs targeting activated genes in cancer cells. It develops products using integrated therapeutic technology (Rx/Dx). …
  • McKesson Corp (MCK):医療機器:M&Aディール及び事業提携情報
    Summary McKesson Corp (McKesson) is a provider of healthcare services and information technology solutions. It distributes pharmaceuticals, medical equipment, and health and beauty care products in North America and overseas. The company also develops and provides decision support software and syste …
  • Weifa ASA (WEIFA)-石油・ガス分野:企業M&A・提携分析
    Summary Weifa ASA (Weifa), formerly Aqualis ASA, is a pharmaceutical company that conducts the research and development, manufacture, distribution and sales of pharmaceutical products, lifestyle products and solutions. The company has over the counter (OTC) pharmaceutical market in Norway offering p …
  • Daiwa House Industry Co., Ltd.:企業の戦略・SWOT・財務分析
    Daiwa House Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Daiwa House Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • SunOpta Inc.:企業の戦略・SWOT・財務情報
    SunOpta Inc. - Strategy, SWOT and Corporate Finance Report Summary SunOpta Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Unfors RaySafe AB:医療機器:M&Aディール及び事業提携情報
    Summary Unfors RaySafe AB (Unfors), formerly Unfors Instruments AB, is a subsidiary of Fluke Biomedical, medical device company that provides solution for the X-ray room consisting of products which collect radiation. The company’s products include RaySafe ThinX, RaySafe X2, RaySafe Solo, RaySafe Xi …
  • TKH Group NV (TWEKA):企業の財務・戦略的SWOT分析
    TKH Group NV (TWEKA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • TTK Prestige Limited:企業の戦略・SWOT・財務分析
    TTK Prestige Limited - Strategy, SWOT and Corporate Finance Report Summary TTK Prestige Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Main Street America Group Inc:企業の戦略的SWOT分析
    Main Street America Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Nanjing Pharmaceutical Co Ltd (600713):企業の財務・戦略的SWOT分析
    Nanjing Pharmaceutical Co Ltd (600713) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • ABO Wind AG:電力:M&Aディール及び事業提携情報
    Summary ABO Wind AG (ABO Wind) develops renewable energy projects in Europe. The company carries out the planning and environmental impact assessment, design, development, and operation of wind power projects and biomass power generating facilities. ABO Wind also provides long-term management or mai …
  • Power Grid Corporation of India Ltd (POWERGRID EQ):企業の財務・戦略的SWOT分析
    Power Grid Corporation of India Ltd (POWERGRID EQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Pan Orient Energy Corp (POE):石油・ガス:M&Aディール及び事業提携情報
    Summary Pan Orient Energy Corp (POE) is an independent upstream oil and gas company. The company has interests in onshore oil and gas assets in Thailand and Indonesia. It also has interests in Andora Energy Corporation, which holds properties in Northern Alberta. Its assets in Thailand include Conce …
  • Eastman Chemical Co (EMN):企業の財務・戦略的SWOT分析
    Eastman Chemical Co (EMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • MedinCell SA:製薬・医療:M&Aディール及び事業提携情報
    Summary MedinCell SA (MedinCell) is a developer of therapeutic solutions for the healthcare market. The company develops and commercializes BEPO, a technology based on custom proprietary copolymers and a biocompatible solvent for long acting injectables. Its BEPO provides a controlled release of the …
  • Golden Grain Energy, LLC:企業の戦略的SWOT分析
    Golden Grain Energy, LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Wartsila Corp (WRT1V):企業の財務・戦略的SWOT分析
    Wartsila Corp (WRT1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • China Pacific Insurance (Group) Co Ltd:企業のM&A・事業提携・投資動向
    China Pacific Insurance (Group) Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Pacific Insurance (Group) Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed repo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆